List of Genpact Cora PharmacoVigilance Customers
Hamilton, x,
Bermuda
Since 2010, our global team of researchers has been studying Genpact Cora PharmacoVigilance customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Genpact Cora PharmacoVigilance for ML and Data Science Platforms from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Genpact Cora PharmacoVigilance for ML and Data Science Platforms include: AstraZeneca, a United Kingdom based Life Sciences organisation with 94300 employees and revenues of $73.98 billion, Eli Lilly, a United States based Life Sciences organisation with 50605 employees and revenues of $65.18 billion, GSK, a United Kingdom based Life Sciences organisation with 69310 employees and revenues of $42.21 billion, Bayer , a Canada based Life Sciences organisation with 1400 employees and revenues of $1.90 billion and many others.
Contact us if you need a completed and verified list of companies using Genpact Cora PharmacoVigilance, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the Artificial Intelligence software purchases.
The Genpact Cora PharmacoVigilance customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of Artificial Intelligence software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
AstraZeneca | Life Sciences | 94300 | $74.0B | United Kingdom | Genpact | Genpact Cora PharmacoVigilance | ML and Data Science Platforms | 2019 | Genpact |
In 2019, AstraZeneca engaged Genpact to deploy Genpact Cora PharmacoVigilance as part of a pharmacovigilance and safety processing services engagement. The initial scope centered on automating and standardizing case intake and reporting workflows across AstraZeneca's global operations to support patient safety processing and regulatory compliance.
Genpact Cora PharmacoVigilance was implemented to provide automated case intake and structured reporting capabilities, consistent with offerings in the ML and Data Science Platforms category. Configuration emphasized standardized ingestion, computational enrichment of safety records, and templated reporting workflows to reduce manual variation in case handling while preserving auditability required for safety reporting.
Genpact served as the delivery partner and operational owner for the solution, embedding Genpact Cora PharmacoVigilance into AstraZeneca pharmacovigilance and safety processing operations. The implementation addressed cross-functional handoffs between safety case triage, medical review, and regulatory reporting functions, with deployment designed to operate at global scale across regions where AstraZeneca maintains pharmacovigilance responsibilities.
Governance focused on process standardization and centralized workflow orchestration under Genpact managed services, with controls to sustain compliance and consistent case handling. The engagement explicitly targeted improved patient-safety processing efficiency and compliance across AstraZeneca's global operations, aligning the Genpact Cora PharmacoVigilance deployment to those operational objectives.
|
 |
Bayer | Life Sciences | 1400 | $1.9B | Canada | Genpact | Genpact Cora PharmacoVigilance | ML and Data Science Platforms | 2017 | n/a |
In 2017, Bayer implemented Genpact Cora PharmacoVigilance to strengthen pharmacovigilance and drug safety operations in Canada. Genpact Cora PharmacoVigilance was deployed as part of Bayer's adoption of ML and Data Science Platforms to introduce AI-driven capabilities into adverse event management and regulatory safety workflows. The implementation emphasized functional modules common to ML and Data Science Platforms, including AI-driven case intake, natural language processing for unstructured safety data, automated triage and prioritization, and signal detection model workflows. Configuration work addressed workflow orchestration and model governance, with model management components embedded into the pharmacovigilance case lifecycle and support for regulatory reporting pipelines. Operational scope centered on Bayer's pharmacovigilance and regulatory safety teams, and governance changes included formalizing model validation checkpoints and data quality controls within case review and escalation processes to ensure oversight of AI outputs.
|
 |
Eli Lilly | Life Sciences | 50605 | $65.2B | United States | Genpact | Genpact Cora PharmacoVigilance | ML and Data Science Platforms | 2017 | n/a |
In 2017 Eli Lilly engaged Genpact to provision Genpact Cora PharmacoVigilance under the ML and Data Science Platforms category to support adverse-event case processing and regulatory reporting. The engagement framed Genpact Cora PharmacoVigilance as a managed pharmacovigilance technology and services layer to strengthen safety operations across regions, aligning with Eli Lilly pharmacovigilance requirements and regulatory submission workflows.
The implementation centered on adverse-event case processing and regulatory reporting modules within Genpact Cora PharmacoVigilance, combined with managed services to operationalize intake, case triage, and report generation. As an ML and Data Science Platforms deployment, the platform was used to apply model-driven analytics for case prioritization and to standardize structured data capture, enabling consistent downstream regulatory outputs.
Operational coverage extended across Eli Lilly safety and pharmacovigilance functions with Genpact delivering the platform and managed processing services across regions. The arrangement positioned Genpact Cora PharmacoVigilance to interface with Eli Lilly safety operations and regional regulatory reporting channels, centralizing case management workflows and operational oversight without disclosing specific system integrations.
Governance was organized around a managed services operating model with Genpact responsible for running pharmacovigilance processes on the Cora platform and Eli Lilly retaining regulatory accountability. Public descriptions indicate the objective was to enhance safety operations across regions, using Genpact Cora PharmacoVigilance to standardize case processing and regulatory reporting practices for pharmacovigilance teams.
|
 |
|
Life Sciences | 69310 | $42.2B | United Kingdom | Genpact | Genpact Cora PharmacoVigilance | ML and Data Science Platforms | 2018 | Genpact |
|
Buyer Intent: Companies Evaluating Genpact Cora PharmacoVigilance
- San Joaquin General Hospital, a India based Communications organization with 42 Employees
- Grunenthal, a Germany based Life Sciences company with 4400 Employees
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||